Jun 27, 2023
Immutep Completes A$80 Million Capital Raise
Jun 20, 2023
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3
Jun 07, 2023
Immutep to Participate at the Jefferies Healthcare Conference
Jun 05, 2023
Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meeting
Jun 02, 2023
Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
